ALX Oncology Holdings Inc (ALXO)

Etorro trading 970x250
ALX Oncology Holdings Inc (ALXO) Logo

About ALX Oncology Holdings Inc

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin’s lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma; and HER2-expressing breast cancer. The company’s pre-clinical products include SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with advanced HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was incorporated in 2015 and is based in Burlingame, California. Address: 866 Malcolm Road, Burlingame, CA, United States, 94010

ALX Oncology Holdings Inc News and around…

Latest news about ALX Oncology Holdings Inc (ALXO) common stock and company :

President And CEO Of Alx Oncology Holdings Sold $910K In Stock
21 Oct, 2021 Yahoo! Finance

Jaume Pons, President And CEO at Alx Oncology Holdings (NASDAQ:ALXO), made a large insider sell on October 19, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that Pons sold 16,700 shares of Alx Oncology Holdings at prices ranging from $54.17 to $55.12. The total transaction amounted to $906,714. Following the transaction, Pons still owns 444,598 shares of Alx Oncology Holdings worth $24,670,743. Alx Oncology Holdin

ALX Oncology Announces First Patient Dosed in ASPEN-05, a Phase 1/2 Study of Evorpacept in Combination with Venetoclax and Azacitidine in Patients with Acute Myeloid Leukemia
21 Oct, 2021 Yahoo! Finance

Second study of evorpacept in patients with myeloid malignanciesSOUTH SAN FRANCISCO, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the first patient has been dosed in the Phase 1/2 ASPEN-05 study evaluating the combination of evorpacept, a next-generation CD47 blocker, with venetoclax and azacitidine for the treatment of pa

Sum Up The Pieces: FYC Could Be Worth $87
19 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Small Cap Growth AlphaDEX Fund ETF (FYC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $87.30 per unit.

IBD Rating Upgrades: Alx Oncology Holding Flashes Improved Relative Price Strength
12 Oct, 2021 FinancialContent

A Relative Strength Rating upgrade for Alx Oncology Holding shows improving technical performance. Will it continue?

ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio
07 Oct, 2021 Yahoo! Finance

Acquisition adds novel and proprietary SHIELD platform for conditional activation of antibodies in tumor microenvironment and proprietary cytotoxic payloads for antibody drug conjugatesExpands ALX Oncology’s pipeline of drug candidates based on expertise in protein engineering and oncology SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company, and ScalmiBio, Inc. (“ScalmiBio”) announced

LABU, ALXO, ACAD, XLRN: Large Inflows Detected at ETF
06 Oct, 2021 FinancialContent

Symbols mentioned in this story: LABU, ALXO, ACAD, XLRN Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand..

Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumo
05 Oct, 2021 FinancialContent

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, and ALX Oncology Holdings Inc. (NASDAQ: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the first patient has been dosed in an open-label, multi-center Phase 1b/2 clinical trial conducted by Zymeworks.

ALX Oncology Announces Four Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
01 Oct, 2021 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced that four abstracts have been accepted for presentation at the SITC 36th Annual Meeting in Washington D.C. from November 10 –14, 2021. The abstracts, which will be presented in a poster session, include new clinical data from ASPEN-01, the ongoing Phase 1b

Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
30 Sep, 2021 FinancialContent

Upgrades For Cabot Oil & Gas Corp (NYSE:COG), Wolfe Research upgraded the previous rating of Peer Perform to Outperform. For the ...

A Peek Into The Markets: US Stock Futures Climb Ahead Of GDP, Jobless Claims Data
30 Sep, 2021 FinancialContent

Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones gained around 90 points in the ...

ALX Oncology Announces Initiation of Investigator-Sponsored Trial of Evorpacept (ALX148) in Patients with Indolent and Aggressive Non-Hodgkin Lymphoma
16 Sep, 2021 FinancialContent

-- Phase 1/2 study conducted at The University of Texas M.D. Anderson Cancer Center

Lightstone Ventures Raises $375 Million Fund
14 Sep, 2021 Yahoo! Finance

Lightstone Ventures today announced the closing of Lightstone Ventures III with $375 million in capital commitments, to invest in early-stage companies developing high impact therapeutics and technologies that have the potential to change patients' lives. The new fund was oversubscribed, exceeding the firm's targeted raise, and included strong support from both new and existing limited partners. With the closing of Fund III, Lightstone Ventures also announced the appointments of Christina Isacso

Alx Oncology Holding Shows Rising Price Performance With Jump To 87 RS Rating
13 Sep, 2021 FinancialContent

Alx Oncology Holding shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 87.

LABU, ALXO, ACAD, XLRN: Large Outflows Detected at ETF
07 Sep, 2021 FinancialContent

Symbols mentioned in this story: LABU, ALXO, ACAD, XLRN Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand..

ALX Oncology Announces Upcoming Virtual Investor Conference Participation
07 Sep, 2021 FinancialContent
Alx Oncology Holding Reaches 80-Plus Relative Strength Rating Benchmark
07 Sep, 2021 FinancialContent

Alx Oncology Holding shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.

The 3 Best Biotech Stocks to Buy Right Now
27 Aug, 2021 FinancialContent

Let your portfolio reflect your personality.

Jon Najarian Sees Unusual Options Activity In Lucid Motors, Kura Oncology And More
24 Aug, 2021 FinancialContent

Jon Najarian spoke on CNBC's "Options Action" about unusually high options activity in Lucid Group Inc (NASDAQ: LCID) on ...

60 Biggest Movers From Yesterday
24 Aug, 2021 FinancialContent

Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be ...

So What's Going On With ALX Oncology's Stock?
23 Aug, 2021 FinancialContent

ALX Oncology Holdings Inc (NASDAQ: ALXO) shares are trading higher by 19.3% at $74.69, potentially in sympathy with Trillium ...

35 Stocks Moving In Monday's Mid-Day Session
23 Aug, 2021 FinancialContent

Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares climbed 187.8% to $17.53 after the company agreed to be acquired by ...

Commit To Buy ALX Oncology Holdings At $60, Earn 69.4% Annualized Using Options
19 Aug, 2021 FinancialContent

Investors eyeing a purchase of ALX Oncology Holdings Inc (ALXO) shares, but cautious about paying the going market price of $62.02/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the October put at the $60 strike, which has a bid at the time of this writing of $6.50..

ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights
12 Aug, 2021 FinancialContent
Stock Upgrades: Alx Oncology Holding Shows Rising Relative Strength
12 Aug, 2021 FinancialContent

A Relative Strength Rating upgrade for Alx Oncology Holding shows improving technical performance. Will it continue?

Notable ETF Inflow Detected - LABU, ALXO, ACAD, XLRN
29 Jul, 2021 FinancialContent

Symbols mentioned in this story: LABU, ALXO, ACAD, XLRN Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand..

This Biotech Stock Is Too Cheap to Ignore
29 Jul, 2021 FinancialContent

Wall Street's short attention span has created an attractive entry point in this once-loved biotech.

ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) and Chemotherapy for the Treatment of Patients with Advanced Head and Ne
28 Jul, 2021 FinancialContent

The second of two distinct randomized Phase 2 studies in collaboration with Merck has been initiated

ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) and Chemotherapy for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma
28 Jul, 2021 Yahoo! Finance

The second of two distinct randomized Phase 2 studies in collaboration with Merck has been initiatedBURLINGAME, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, in partnership with Merck, known as MSD outside the United States and Canada, today announced the first patient has been dosed in the Phase 2 ASPEN-04 study evaluating the combination

Alx Oncology Holding Gets Technical Rating Upgrade
22 Jul, 2021 FinancialContent

A Relative Strength Rating upgrade for Alx Oncology Holding shows improving technical performance. Will it continue?

ALX Oncology Holdings Inc. (ALXO) Upgraded to Buy: Here's What You Should Know
15 Jul, 2021 Yahoo! Finance

ALX Oncology Holdings Inc. (ALXO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ALX Oncology Holdings Inc (ALXO) is a NASDAQ Common Stock listed in , ,

970x250